Posted: November 13, 2020 by quartzdev
New Policies for Biologics with Biosimilars
Effective January 1, 2021, Quartz will no longer cover brand biologics when a biosimilar is available unless the brand is being used for intravitreal injections. At this time, Quartz does not have a preference as to which biosimilar is used.
Biosimilars of the following products will be covered without prior authorization:
Biosimilars of the following products will require an approved prior authorization for coverage:
Please refer to the most up to date list of provider administered medications that require prior authorization.
After January 1, 2021, claims for the brand biologic will be denied unless there is an approved prior authorization or the brand is being used for intravitreal injections. If your patient has already been switched to the biosimilar, thank you. If they have not, they will have coverage of the brand biologic through December 31, 2020, and will need to be changed to the biosimilar for any doses after January 1, 2021.
- If your patient is a Quartz Medicare Advantage member currently receiving one of the above medications and they have not switched to the biosimilar, they will have coverage of the brand until at least December 31, 2021. After that time, if our criteria have an approval limit, your patient would require a renewed prior authorization approval for Quartz to continue covering the medication.
Quartz Launches Mental Well-Being Programs with AbleToRead more
Quartz Continues Partnership with Milwaukee Brewers for 2023 SeasonRead more
Welcome to better well-beingRead more
Quartz Receives Richard L. Doyle Award for Successful Prior Authorization AutomationRead more
Updates to claims edit software systemRead more